Devrimed

Devrimed is a biotechnology company focused on developing novel small molecule therapeutics for the treatment of cancer and inflammatory diseases. The company's primary focus is on targeting the prostaglandin E2 (PGE2) pathway, specifically through the development of potent and selective Prostaglandin E receptor 4 (EP4) antagonists. By inhibiting the EP4 receptor, Devrimed aims to overcome immune suppression within the tumor microenvironment, thereby enhancing the efficacy of existing immunotherapies and providing new options for patients with treatment-resistant solid tumors. The company is currently advancing its lead programs through pre-clinical development with the goal of entering clinical trials.